Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 13, 2025 | -$0.45 | -$0.45 | Beat |
| Aug 14, 2025 | -$0.45 | -$0.62 | Miss |
| May 13, 2025 | -$0.33 | -$0.51 | Miss |
| Mar 13, 2025 | -$0.25 | -$0.49 | Miss |
| Nov 7, 2024 | -$0.38 | -$0.94 | Miss |
| Aug 13, 2024 | -$0.72 | -$0.93 | Miss |